Back to Search

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies


  • Protocol Number: 201510089
  • Principal Investigator: Govindan, Ramaswamy
  • Cancer Types: Gene & Cellular Immunotherapy, GU: Bladder, Kidney, Prostate, Testicular

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions